Helen Wong, Director of Granite Global Ventures, has joined the Bridge board. Helen is a founding member of GGV and is based in its Shanghai office. In addition to her board seats at various other GGV portfolio companies, Helen has been involved in GGV's healthcare investments and has helped several U.S. portfolio companies develop their China strategies. She was selected as the first international Kauffman Fellow, a fellowship sponsored by the Kauffman Center for Entrepreneurial Leadership.
The capital raised will be used to accelerate growth of Bridge's preclinical operations in China, as well as to support M&A activities, including its recent acquisition of the Preclinical Division of Gene Logic Inc. of Gaithersburg, Maryland in December, 2006. In addition, Bridge plans to initiate construction of a second vivarium in Beijing shortly.
About Granite Global Ventures
Granite Global Ventures is a leader in expansion-stage venture capital investments in the United States and Asia. Focused on expanding global innovation, GGV's highly diverse team manages over $800 million from its offices in Silicon Valley, Shanghai, and Singapore. The firm invests across a range of sectors in information technology, services and healthcare, as well as emerging industry segments in Asia. GGV has provided capital and helped accelerate international business development for its worldwide portfolio of high-growth companies, particularly in the U.S. and China. GGV's portfolio includes Alibaba.com (combined with Yahoo!), Xenoport (NASDAQ:XNPT - News), AAC Acoustics (SEHK:2018 - News), Biosensors (SGX:B20), Isilon (NASDAQ:ISLN - News), and Boston-Power. Recent exits include Sirna Therapeutics (acquired by Merck), Qpass (acquired by Amdocs), Xfire (acquired by Viacom), and Oculex (acquired by Allergan). The total market value of GGV's exits since the firm's formation in 2000 now exceeds $7 billion. For more information, please visit www.ggvc.com.
About Bridge Pharmaceuticals
Bridge is a preclinical CRO with state-of-the-art facilities in Gaithersburg, Maryland and Beijing, China, with over 300 employees, providing US GLP compliant pre-clinical contract pharmaceutical, biologics and vaccine development services. Services include general and specialized toxicology, developmental and reproductive toxicology (DART), safety pharmacology, carcinogenicity testing and vaccine development in support of IND and NDA submissions. Studies are backed by in-house bioanalytical chemistry, immunoassay as well as histopathology and clinical pathology services that are all under the direction of US board certified pathologists and toxicologists. For more information, visit www.bridgecro.com or contact the individuals below.
Copyright © 2007, Bridge Pharmaceuticals, Inc. All rights reserved.
Contact: For Bridge Pharmaceuticals In US Mark Xu, 650-588-1188 ext. 104 mxu@bridgepharmaceuticals.com In China Tina Huang, 8610 80728800 thuang@bridgepharmaceuticals.com
Source: Bridge Pharmaceuticals
